The First Affiliated Hospital of Xiamen University
🇨🇳China
Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML
- First Posted Date
- 2024-12-17
- Last Posted Date
- 2024-12-17
- Target Recruit Count
- 30
- Registration Number
- NCT06737523
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer
Not Applicable
Recruiting
- Conditions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-12-18
- Target Recruit Count
- 100
- Registration Number
- NCT06696326
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
IMRT Combined with Lobaplatin-based CCRT in Nasopharyngeal Carcinoma
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Target Recruit Count
- 32
- Registration Number
- NCT06688175
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
SBRT Combined with Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2024-11-06
- Last Posted Date
- 2024-11-06
- Target Recruit Count
- 20
- Registration Number
- NCT06676722
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-10-23
- Target Recruit Count
- 18
- Registration Number
- NCT06651866
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-10-23
- Target Recruit Count
- 53
- Registration Number
- NCT06651853
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors
- First Posted Date
- 2024-09-04
- Last Posted Date
- 2024-09-04
- Target Recruit Count
- 50
- Registration Number
- NCT06584006
- Locations
- 🇨🇳
Zhijuan Lin, Xiamen, Fujian, China
Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-09-03
- Target Recruit Count
- 5
- Registration Number
- NCT06581640
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2024-08-14
- Target Recruit Count
- 39
- Registration Number
- NCT06553352
- Locations
- 🇨🇳
Bing Xu, Xiamen, Fujian, China
Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-07-31
- Target Recruit Count
- 50
- Registration Number
- NCT06530004
- Locations
- 🇨🇳
First affiliated hospital of xiamen university, Xiamen, Fujian, China
© Copyright 2024. All Rights Reserved by MedPath